Skip to content
TRACON Pharmaceuticals Logo TRACON Pharmaceuticals Logo TRACON Pharmaceuticals Logo
  • ABOUT
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORY BOARD
  • PIPELINE
    • ENVAFOLIMAB KN035
    • TRC102
    • YH001
  • CLINICAL TRIALS
    • EXPANDED ACCESS POLICY
  • PARTNERS
  • NEWS
    • PRESS RELEASES
    • VIDEO PRESENTATIONS
  • INVESTORS
    • EVENTS & PRESENTATIONS
    • CORPORATE GOVERNANCE
    • SEC FILINGS
    • ANNUAL REPORTS & PROXIES
    • QUARTERLY REPORTS
    • STOCK QUOTE
    • HISTORICAL PRICE LOOKUP
    • INVESTMENT CALCULATOR
    • INVESTOR FAQ
  • CONTACT
  • COMMUNITY

OUR GOAL IS TO BE A LEADER IN THE DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH CANCER AND OTHER DISEASES OF HIGH UNMET NEED Stock Quote
Stock Quoteadmin2023-06-22T08:48:11-07:00

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, Our lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Links

ABOUT
PIPELINE
CLINICAL TRIALS
PARTNERS
NEWS
INVESTORS
CONTACT
COMMUNITY

Contact Us

  4350 La Jolla Village Drive, Suite 800 San Diego, CA 92122

 (858) 550-0780

 (858) 550-0786

  info@traconpharma.com

TRACON Pharmaceuticals © 2023 | Digital Endeavor Websites

Page load link
Go to Top